ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature

Anti-Cancer Drugs

Volumn 20, Issue 6, 2009, Pages 483-492

  Luo, Yanping ^a   Hradil, Vincent P ^a   Frost, David J ^a   Rosenberg, Saul H ^a   Gordon, Gary B ^a   Morgan, Sherry J ^a   Gagne, Gerard D ^a   Cox, Bryan F ^a   Tahir, Stephen K ^a   Fox, Gerard B ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

ABT 751; Dynamic contrast enhanced magnetic resonance imaging; Perfusion; Rat; Tumor; Vascular disrupting agent

Indexed keywords

GADOLINIUM PENTETATE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; TUBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG UPTAKE; ENDOTHELIUM CELL; FEMALE; GLIOMA CELL; IN VITRO STUDY; MICROTUBULE; MUSCLE PERFUSION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; BINDING SITES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MICROFILAMENTS; MICROTUBULES; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN BINDING; RATS; RATS, INBRED F344; SULFONAMIDES; TUBULIN;

EID: 67249084753     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e32832c0acf     Document Type: Article

References (55)

1. Dhanabal M, Jeffers M, Larochelle WJ. Anti-angiogenic therapy as a cancer treatment paradigm. Curr Med Chem Anticancer Agents 2005; 5:115-130. (Pubitemid 40347985)
2. Petersen I. Antiangiogenesis, anti-VEGF(R) and outlook. Recent Results Cancer Res 2007; 176:189-199.
3. Harris AL. Antiangiogenesis for cancer therapy. Lancet 1997; 349 (Suppl 2):SII13-SII15. (Pubitemid 27212054)
4. Schlaeppi JM, Wood JM. Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors. Cancer Metastasis Rev 1999; 18:473-481. (Pubitemid 30365325)
5. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000; 60:2178-2189. (Pubitemid 30225181)
6. Kanthou C, Tozer GM. Tumour targeting by microtubule-depolymerizing vascular disrupting agents. Expert Opin Ther Targets 2007; 11:1443-1457. (Pubitemid 350200480)
7. Chaplin DJ, Horsman MR, Siemann DW. Current development status of small-molecule vascular disrupting agents. Curr Opin Investig Drugs 2006; 7:522-528. (Pubitemid 43891030)
8. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 1996; 27:S86-S88. (Pubitemid 26237935)
9. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10:415-427. (Pubitemid 38173977)
10. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100:2491-2499. (Pubitemid 38715753)
11. Warren B. The vascular morphology of tumors. In: Peterson HI. Tumor blood circulation. Boca Raton: CRC Press; 1979. pp. 1-47.
12. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60:1388-1393. (Pubitemid 30152012)
13. Hill SA, Lonergan SJ, Denekamp J, Chaplin DJ. Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer 1993; 29A:1320-1324. (Pubitemid 23169906)
14. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi LJ. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27:482-487.
15. West CM, Price P. Combretastatin A4 phosphate. Anticancer Drugs 2004; 15:179-187. (Pubitemid 38429409)
16. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002; 54:1491-1496. (Pubitemid 35380054)
17. Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999; 59:1626-1634. (Pubitemid 29160136)
18. Micheletti G, Poli M, Borsotti P, Martinelli M, Imberti B, Taraboletti G, et al. Vascular-targeting activity of ZD6126, a novel tubulin-binding agent. Cancer Res 2003; 63:1534-1537. (Pubitemid 36373640)
19. Davis PD, Dougherty GJ, Blakey DC, Galbraith SM, Tozer GM, Holder AL, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002; 62:7247-7253. (Pubitemid 36025246)
20. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003; 89:1334-1344. (Pubitemid 37363426)
21. Yoshimatsu K, Yamaguchi A, Yoshino H, Koyanagi N, Kitoh K. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997; 57:3208-3213. (Pubitemid 27351737)
22. Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, et al. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res 1994; 54:1702-1706. (Pubitemid 24116173)
23. Funahashi Y, Koyanagi N, Kitoh K. Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine colon 38 tumor. Cancer Chemother Pharmacol 2001; 47:179-184. (Pubitemid 32662324)
24. Morton CL, Favours EG, Mercer KS, Boltz CR, Crumpton JC, Tucker C, et al. Evaluation of ABT-751 against childhood cancer models in vivo. Invest New Drugs 2007; 25:285-295. (Pubitemid 46944850)
25. Yee KW, Hagey A, Verstovsek S, Cortes J, Garcia-Manero G, O'Brien SM, et al. Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin Cancer Res 2005; 11:6615-6624. (Pubitemid 41339002)
26. Hande KR, Hagey A, Berlin J, Cai Y, Meek K, Kobayashi H, et al. The pharmacokinetics and safety of ABT-751, a novel, orally bioavailable sulfonamide antimitotic agent: results of a phase 1 study. Clin Cancer Res 2006; 12:2834-2840. (Pubitemid 43752124)
27. Yamamoto K, Noda K, Yoshimura A, Fukuoka M, Furuse K, Niitani H. Phase I study of E7010. Cancer Chemother Pharmacol 1998; 42:127-134. (Pubitemid 28267293)
28. Iwamoto Y, Nishio K, Fukumoto H, Yoshimatsu K, Yamakido M, Saijo N. Preferential binding of E7010 to murine beta 3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn J Cancer Res 1998; 89:954-962. (Pubitemid 28486822)
29. Nihei Y, Suzuki M, Okano A, Tsuji T, Akiyama Y, Tsuruo T, et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Jpn J Cancer Res 1999; 90:1387-1395. (Pubitemid 30032079)
30. Segreti JA, Polakowski JS, Koch KA, Marsh KC, Bauch JL, Rosenberg SH, et al. Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother Pharmacol 2004; 54:273-281. (Pubitemid 39141745)
31. Luo Y, Hradil VP, Mohning KM, Nuss ME, Sham HL, Rosenberg SH, et al. Evaluation of anti-vascular effects of ABT-751 and A-318315 using dynamic contrast enhanced MRI (DCE-MRI). Proc Int Soc Magn Reson Med 2002; 3:2140.
32. O'Connor JP, Jackson A, Parker GJ, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer 2007; 96:189-195. (Pubitemid 46160619)
33. Robinson SP, McIntyre DJ, Checkley D, Tessier JJ, Howe FA, Griffiths JR, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003; 88:1592-1597. (Pubitemid 36713788)
34. Maxwell RJ, Wilson J, Prise VE, Vojnovic B, Rustin GJ, Lodge MA, et al. Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI. NMR Biomed 2002; 15:89-98. (Pubitemid 34213398)
35. McIntyre DJ, Robinson SP, Howe FA, Griffiths JR, Ryan AJ, Blakey DC, et al. Single dose of the antivascular agent, ZD6126 (N-acetylcolchinol-O- phosphate), reduces perfusion for at least 96 h in the GH3 prolactinoma rat tumor model. Neoplasia 2004; 6:150-157. (Pubitemid 38544603)
36. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21:4428-4438. (Pubitemid 46621821)
37. Tofts PS. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging. J Magn Reson Imaging 1997; 7:91-101. (Pubitemid 28365643)
38. Evelhoch JL, LoRusso PM, He Z, DelProposto Z, Polin L, Corbett TH, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004; 10:3650-3657. (Pubitemid 38697598)
39. Wilke N, Jerosch-Herold M, Wang Y, Huang Y, Christensen BV, Stillman AE, et al. Myocardial perfusion reserve: assessment with multisection, quantitative, first-pass MR imaging. Radiology 1997; 204:373-384. (Pubitemid 27337482)
40. Luo Y, Mohning KM, Hradil VP, Wessale JL, Segreti JA, Nuss ME, et al. Evaluation of tissue perfusion in a rat model of hind-limb muscle ischemia using dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging 2002; 16:277-283. (Pubitemid 34920426)
41. Verstraete KL, Van der Woude HJ, Hogendoorn PC, De-Deene Y, Kunnen M, Bloem JL. Dynamic contrast-enhanced MR imaging of musculoskeletal tumors: basic principles and clinical applications. J Magn Reson Imaging 1996; 6:311-321. (Pubitemid 126701461)
42. Chen J, Wu W, Tahir SK, Kroeger PE, Rosenberg SH, Cowsert LM, et al. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. Neoplasia 2000; 2:235-241. (Pubitemid 30346079)
43. Tozer GM, Akerman S, Cross NA, Barber PR, Bjorndahl MA, Greco O, et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res 2008; 68:2301-2311.
44. Yokoi A, Kuromitsu J, Kawai T, Nagasu T, Sugi NH, Yoshimatsu K, et al. Profiling novel sulfonamide antitumor agents with cell-based phenotypic screens and array-based gene expression analysis. Mol Cancer Ther 2002; 1:275-286.
45. Fox E, Maris JM, Widemann BC, Meek K, Goodwin A, Goodspeed W, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006; 12:4882-4887. (Pubitemid 44338575)
46. Fox E, Maris JM, Widemann BC, Goodspeed W, Goodwin A, Kromplewski M, et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res 2008; 14:1111-1115. (Pubitemid 351302558)
47. Mauer AM, Cohen EE, Ma PC, Kozloff MF, Schwartzberg L, Coates Al, et al. A phase II study of ABT-751 in patients with advanced non-small cell lung cancer. J Thorac Oncol 2008; 3:631-636. (Pubitemid 351787308)
48. Horsman MR, Chaplin DJ, Overgaard J. The use of blood flow modifiers to improve the treatment response of solid tumors. Radiother Oncol 1991; 20 (Suppl 1):47-52.
49. Jorgensen TJ, Tian H, Joseph IB, Menon K, Frost D. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth. Cancer Chemother Pharmacol 2007; 59:725-732. (Pubitemid 46440594)
50. Hori K, Furumoto S, Kubota K. Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Cancer Sci 2008; 99:1485-1491. (Pubitemid 351761742)
51. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 2004; 10:7671-7676. (Pubitemid 39557531)
52. Hokland SL, Horsman MR. The new vascular disrupting agent combretastatin-A1-disodium-phosphate (OXi4503) enhances tumour response to mild hyperthermia and thermoradiosensitization. Int J Hyperthermia 2007; 23:599-606. (Pubitemid 350187055)
53. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999; 19:189-195. (Pubitemid 29168237)
54. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003; 51:43-52. (Pubitemid 36057022)
55. Soltau J, Drevs J. ZD-6126 AstraZeneca. J Drugs 2004; 7:380-387.